健康科学杂志

  • 国际标准期刊号: 1108-7366
  • 期刊 h 指数: 51
  • 期刊引用分数: 10.69
  • 期刊影响因子: 9.13
索引于
  • Genamics 期刊搜索
  • 中国知网(CNKI)
  • 引用因子
  • CINAHL 完整
  • 西马戈
  • 电子期刊图书馆
  • 研究期刊索引目录 (DRJI)
  • EMCare
  • OCLC-WorldCat
  • 大学教育资助委员会
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • 谷歌学术
  • 夏尔巴罗密欧
  • 秘密搜索引擎实验室
分享此页面

抽象的

Is there a Correlation between Changes in Hydroxychloroquine Use and Mortality Rates from COVID-19?

Elena Filipova, Elitsa Gotseva, Katya Uzunova, Velichka Pavlova, Silvia Hristova, Krassimir Kalinov and Toni Vekov

Currently there is an active search for vaccines or therapeutics against the newly emergent Coronavirus disease (COVID-19). A large number of countries have published documents with recommendations for health professionals which are similar in nature. However, there are differences worth discussing. We aimed to determine if there is any connection between changes in hydroxychloroquine use and death rates from COVID-19 worldwide. We presented data for changes in hydroxychloroquine use for 56 countries for the period January 2019 to April 2020. Mortality rate was extrapolated as case fatality rate from data about total deaths to total number of cases for each country. The Pearson’s correlation coefficient is -0.215. Together with the p value of 0.112, it points to lack of statistically significant relation. We formed three clusters and analysed the differences between the two parameters. There is a statistically significant difference in mortality rates and changes in hydroxychloroquine use. Eta coefficient and eta squared are 0.750 and 0.563 for the increase in hydroxychloroquine use and 0.853 and 0.727 for the mortality rate respectively. Correlation between changes in hydroxychloroquine use and mortality rate from COVID-19 is non-linear with high eta coefficient but available data is not enough to fully characterize it.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证